{"id":2586,"date":"2025-10-08T09:00:00","date_gmt":"2025-10-08T13:00:00","guid":{"rendered":"https:\/\/glycovax.com\/?p=2586"},"modified":"2025-10-07T11:19:35","modified_gmt":"2025-10-07T15:19:35","slug":"glycovax-le-cnrc-et-luniversite-de-montreal-developpent-un-vaccin-contre-la-bacterie-pseudomonas-aeruginosa-pa-avec-le-soutien-du-cqdm","status":"publish","type":"post","link":"https:\/\/glycovax.com\/fr\/glycovax-le-cnrc-et-luniversite-de-montreal-developpent-un-vaccin-contre-la-bacterie-pseudomonas-aeruginosa-pa-avec-le-soutien-du-cqdm\/","title":{"rendered":"Glycovax, le CNRC et l&rsquo;Universit\u00e9 de Montr\u00e9al, d\u00e9veloppent un vaccin contre la bact\u00e9rie Pseudomonas aeruginosa (Pa), avec le soutien du CQDM"},"content":{"rendered":"\n<p>Les maladies respiratoires, qui se d\u00e9veloppent en particulier dans les h\u00f4pitaux, comme celles r\u00e9sultant des infections \u00e0 <em>Pa<\/em>, sont un fl\u00e9au contre lequel il n&rsquo;existe actuellement aucun vaccin efficace. Souvent r\u00e9sistante aux antibiotiques, l\u2019infection par <em>Pa<\/em> est une cause principale des maladies li\u00e9es \u00e0 l\u2019hospitalisation et des infections parfois fatales chez les personnes atteintes de fibrose kystique. &nbsp;<\/p>\n\n\n\n<p>Glycovax Pharma a optimis\u00e9 la fabrication du vaccin GVX-PA-01, \u00e0 partir d\u2019un antig\u00e8ne identifi\u00e9 par le Conseil national de recherches du Canada (CNRC), en y int\u00e9grant l\u2019adjuvant SLA. Glycovax poursuit le d\u00e9veloppement pr\u00e9clinique du vaccin en collaboration avec le CNRC et la Facult\u00e9 de m\u00e9decine v\u00e9t\u00e9rinaire de l\u2019Universit\u00e9 de Montr\u00e9al, gr\u00e2ce \u00e0 une subvention de 467 661 $ du CQDM au nom du Gouvernement du Qu\u00e9bec.<\/p>\n\n\n\n<p><a href=\"https:\/\/glycovax.com\/wp-content\/uploads\/2025\/10\/Glycovax-CNRC-UdM-CQDM-FR-06-10-25-vf14.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Lire la suite&#8230;<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Les maladies respiratoires, qui se d\u00e9veloppent en particulier dans les h\u00f4pitaux, comme celles r\u00e9sultant des infections \u00e0 Pa, sont un fl\u00e9au contre lequel il n&rsquo;existe actuellement aucun vaccin efficace. Souvent r\u00e9sistante aux antibiotiques, l\u2019infection par Pa est une cause principale des maladies li\u00e9es \u00e0 l\u2019hospitalisation et des infections parfois fatales chez les personnes atteintes de&hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[95],"tags":[94],"class_list":["post-2586","post","type-post","status-publish","format-standard","hentry","category-nouvelles","tag-featured-fr"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vaccin contre Pseudomonas aeruginosa | Glycovax obtient une licence du CNRC<\/title>\n<meta name=\"description\" content=\"Glycovax Pharma obtient une licence du CNRC pour d\u00e9velopper un vaccin semi-synth\u00e9tique contre Pseudomonas aeruginosa, une bact\u00e9rie nosocomiale prioritaire selon l\u2019OMS.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/glycovax.com\/fr\/glycovax-le-cnrc-et-luniversite-de-montreal-developpent-un-vaccin-contre-la-bacterie-pseudomonas-aeruginosa-pa-avec-le-soutien-du-cqdm\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vaccin contre Pseudomonas aeruginosa | Glycovax obtient une licence du CNRC\" \/>\n<meta property=\"og:description\" content=\"Glycovax Pharma obtient une licence du CNRC pour d\u00e9velopper un vaccin semi-synth\u00e9tique contre Pseudomonas aeruginosa, une bact\u00e9rie nosocomiale prioritaire selon l\u2019OMS.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/glycovax.com\/fr\/glycovax-le-cnrc-et-luniversite-de-montreal-developpent-un-vaccin-contre-la-bacterie-pseudomonas-aeruginosa-pa-avec-le-soutien-du-cqdm\/\" \/>\n<meta property=\"og:site_name\" content=\"Glycovax Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-08T13:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/glycovax.com\/wp-content\/uploads\/2025\/08\/glycovax-7i9a7324-visuel-FR-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2048\" \/>\n\t<meta property=\"og:image:height\" content=\"1152\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Claude Dagenais\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Claude Dagenais\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-le-cnrc-et-luniversite-de-montreal-developpent-un-vaccin-contre-la-bacterie-pseudomonas-aeruginosa-pa-avec-le-soutien-du-cqdm\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-le-cnrc-et-luniversite-de-montreal-developpent-un-vaccin-contre-la-bacterie-pseudomonas-aeruginosa-pa-avec-le-soutien-du-cqdm\\\/\"},\"author\":{\"name\":\"Claude Dagenais\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#\\\/schema\\\/person\\\/791c61a78825c9dc04135e2ceaca3883\"},\"headline\":\"Glycovax, le CNRC et l&rsquo;Universit\u00e9 de Montr\u00e9al, d\u00e9veloppent un vaccin contre la bact\u00e9rie Pseudomonas aeruginosa (Pa), avec le soutien du CQDM\",\"datePublished\":\"2025-10-08T13:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-le-cnrc-et-luniversite-de-montreal-developpent-un-vaccin-contre-la-bacterie-pseudomonas-aeruginosa-pa-avec-le-soutien-du-cqdm\\\/\"},\"wordCount\":167,\"publisher\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#organization\"},\"keywords\":[\"Featured\"],\"articleSection\":[\"Nouvelles\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-le-cnrc-et-luniversite-de-montreal-developpent-un-vaccin-contre-la-bacterie-pseudomonas-aeruginosa-pa-avec-le-soutien-du-cqdm\\\/\",\"url\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-le-cnrc-et-luniversite-de-montreal-developpent-un-vaccin-contre-la-bacterie-pseudomonas-aeruginosa-pa-avec-le-soutien-du-cqdm\\\/\",\"name\":\"Vaccin contre Pseudomonas aeruginosa | Glycovax obtient une licence du CNRC\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#website\"},\"datePublished\":\"2025-10-08T13:00:00+00:00\",\"description\":\"Glycovax Pharma obtient une licence du CNRC pour d\u00e9velopper un vaccin semi-synth\u00e9tique contre Pseudomonas aeruginosa, une bact\u00e9rie nosocomiale prioritaire selon l\u2019OMS.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-le-cnrc-et-luniversite-de-montreal-developpent-un-vaccin-contre-la-bacterie-pseudomonas-aeruginosa-pa-avec-le-soutien-du-cqdm\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-le-cnrc-et-luniversite-de-montreal-developpent-un-vaccin-contre-la-bacterie-pseudomonas-aeruginosa-pa-avec-le-soutien-du-cqdm\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-le-cnrc-et-luniversite-de-montreal-developpent-un-vaccin-contre-la-bacterie-pseudomonas-aeruginosa-pa-avec-le-soutien-du-cqdm\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Glycovax, le CNRC et l&#8217;Universit\u00e9 de Montr\u00e9al, d\u00e9veloppent un vaccin contre la bact\u00e9rie Pseudomonas aeruginosa (Pa), avec le soutien du CQDM\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/\",\"name\":\"Glycovax Pharma\",\"description\":\"Saving millions of lives by using the power of advanced medical nanotechnology.\",\"publisher\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#organization\"},\"alternateName\":\"Glycovax\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#organization\",\"name\":\"Glycovax Pharma\",\"alternateName\":\"Glycovax\",\"url\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/glycovax.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Glycovax-Pharma-carre.png\",\"contentUrl\":\"https:\\\/\\\/glycovax.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Glycovax-Pharma-carre.png\",\"width\":1200,\"height\":1200,\"caption\":\"Glycovax Pharma\"},\"image\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#\\\/schema\\\/person\\\/791c61a78825c9dc04135e2ceaca3883\",\"name\":\"Claude Dagenais\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f4b8cea30a420f348ecee86e20e8aa60d5506584eaad9180873c59b61f2260fe?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f4b8cea30a420f348ecee86e20e8aa60d5506584eaad9180873c59b61f2260fe?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f4b8cea30a420f348ecee86e20e8aa60d5506584eaad9180873c59b61f2260fe?s=96&d=mm&r=g\",\"caption\":\"Claude Dagenais\"},\"sameAs\":[\"https:\\\/\\\/twohumans.com\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vaccin contre Pseudomonas aeruginosa | Glycovax obtient une licence du CNRC","description":"Glycovax Pharma obtient une licence du CNRC pour d\u00e9velopper un vaccin semi-synth\u00e9tique contre Pseudomonas aeruginosa, une bact\u00e9rie nosocomiale prioritaire selon l\u2019OMS.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/glycovax.com\/fr\/glycovax-le-cnrc-et-luniversite-de-montreal-developpent-un-vaccin-contre-la-bacterie-pseudomonas-aeruginosa-pa-avec-le-soutien-du-cqdm\/","og_locale":"fr_FR","og_type":"article","og_title":"Vaccin contre Pseudomonas aeruginosa | Glycovax obtient une licence du CNRC","og_description":"Glycovax Pharma obtient une licence du CNRC pour d\u00e9velopper un vaccin semi-synth\u00e9tique contre Pseudomonas aeruginosa, une bact\u00e9rie nosocomiale prioritaire selon l\u2019OMS.","og_url":"https:\/\/glycovax.com\/fr\/glycovax-le-cnrc-et-luniversite-de-montreal-developpent-un-vaccin-contre-la-bacterie-pseudomonas-aeruginosa-pa-avec-le-soutien-du-cqdm\/","og_site_name":"Glycovax Pharma","article_published_time":"2025-10-08T13:00:00+00:00","og_image":[{"width":2048,"height":1152,"url":"https:\/\/glycovax.com\/wp-content\/uploads\/2025\/08\/glycovax-7i9a7324-visuel-FR-scaled.jpg","type":"image\/jpeg"}],"author":"Claude Dagenais","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Claude Dagenais","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/glycovax.com\/fr\/glycovax-le-cnrc-et-luniversite-de-montreal-developpent-un-vaccin-contre-la-bacterie-pseudomonas-aeruginosa-pa-avec-le-soutien-du-cqdm\/#article","isPartOf":{"@id":"https:\/\/glycovax.com\/fr\/glycovax-le-cnrc-et-luniversite-de-montreal-developpent-un-vaccin-contre-la-bacterie-pseudomonas-aeruginosa-pa-avec-le-soutien-du-cqdm\/"},"author":{"name":"Claude Dagenais","@id":"https:\/\/glycovax.com\/fr\/#\/schema\/person\/791c61a78825c9dc04135e2ceaca3883"},"headline":"Glycovax, le CNRC et l&rsquo;Universit\u00e9 de Montr\u00e9al, d\u00e9veloppent un vaccin contre la bact\u00e9rie Pseudomonas aeruginosa (Pa), avec le soutien du CQDM","datePublished":"2025-10-08T13:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/glycovax.com\/fr\/glycovax-le-cnrc-et-luniversite-de-montreal-developpent-un-vaccin-contre-la-bacterie-pseudomonas-aeruginosa-pa-avec-le-soutien-du-cqdm\/"},"wordCount":167,"publisher":{"@id":"https:\/\/glycovax.com\/fr\/#organization"},"keywords":["Featured"],"articleSection":["Nouvelles"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/glycovax.com\/fr\/glycovax-le-cnrc-et-luniversite-de-montreal-developpent-un-vaccin-contre-la-bacterie-pseudomonas-aeruginosa-pa-avec-le-soutien-du-cqdm\/","url":"https:\/\/glycovax.com\/fr\/glycovax-le-cnrc-et-luniversite-de-montreal-developpent-un-vaccin-contre-la-bacterie-pseudomonas-aeruginosa-pa-avec-le-soutien-du-cqdm\/","name":"Vaccin contre Pseudomonas aeruginosa | Glycovax obtient une licence du CNRC","isPartOf":{"@id":"https:\/\/glycovax.com\/fr\/#website"},"datePublished":"2025-10-08T13:00:00+00:00","description":"Glycovax Pharma obtient une licence du CNRC pour d\u00e9velopper un vaccin semi-synth\u00e9tique contre Pseudomonas aeruginosa, une bact\u00e9rie nosocomiale prioritaire selon l\u2019OMS.","breadcrumb":{"@id":"https:\/\/glycovax.com\/fr\/glycovax-le-cnrc-et-luniversite-de-montreal-developpent-un-vaccin-contre-la-bacterie-pseudomonas-aeruginosa-pa-avec-le-soutien-du-cqdm\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/glycovax.com\/fr\/glycovax-le-cnrc-et-luniversite-de-montreal-developpent-un-vaccin-contre-la-bacterie-pseudomonas-aeruginosa-pa-avec-le-soutien-du-cqdm\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/glycovax.com\/fr\/glycovax-le-cnrc-et-luniversite-de-montreal-developpent-un-vaccin-contre-la-bacterie-pseudomonas-aeruginosa-pa-avec-le-soutien-du-cqdm\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/glycovax.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Glycovax, le CNRC et l&#8217;Universit\u00e9 de Montr\u00e9al, d\u00e9veloppent un vaccin contre la bact\u00e9rie Pseudomonas aeruginosa (Pa), avec le soutien du CQDM"}]},{"@type":"WebSite","@id":"https:\/\/glycovax.com\/fr\/#website","url":"https:\/\/glycovax.com\/fr\/","name":"Glycovax Pharma","description":"Saving millions of lives by using the power of advanced medical nanotechnology.","publisher":{"@id":"https:\/\/glycovax.com\/fr\/#organization"},"alternateName":"Glycovax","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/glycovax.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/glycovax.com\/fr\/#organization","name":"Glycovax Pharma","alternateName":"Glycovax","url":"https:\/\/glycovax.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/glycovax.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/glycovax.com\/wp-content\/uploads\/2025\/04\/Glycovax-Pharma-carre.png","contentUrl":"https:\/\/glycovax.com\/wp-content\/uploads\/2025\/04\/Glycovax-Pharma-carre.png","width":1200,"height":1200,"caption":"Glycovax Pharma"},"image":{"@id":"https:\/\/glycovax.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/glycovax.com\/fr\/#\/schema\/person\/791c61a78825c9dc04135e2ceaca3883","name":"Claude Dagenais","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/f4b8cea30a420f348ecee86e20e8aa60d5506584eaad9180873c59b61f2260fe?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f4b8cea30a420f348ecee86e20e8aa60d5506584eaad9180873c59b61f2260fe?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f4b8cea30a420f348ecee86e20e8aa60d5506584eaad9180873c59b61f2260fe?s=96&d=mm&r=g","caption":"Claude Dagenais"},"sameAs":["https:\/\/twohumans.com\/"]}]}},"_links":{"self":[{"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/posts\/2586","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/comments?post=2586"}],"version-history":[{"count":1,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/posts\/2586\/revisions"}],"predecessor-version":[{"id":2588,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/posts\/2586\/revisions\/2588"}],"wp:attachment":[{"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/media?parent=2586"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/categories?post=2586"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/tags?post=2586"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}